Produktname:methyl 4-aminopyridine-2-carboxylate

IUPAC Name:methyl 4-aminopyridine-2-carboxylate

CAS:71469-93-7
Molekulare Formel:C7H8N2O2
Reinheit:95%+
Katalognummer:CM108498
Molekulargewicht:152.15

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM108498-25g in stock ȯƿƿ
CM108498-100g in stock ȐƥȐ
CM108498-500g in stock ǑǑǫȐ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:71469-93-7
Molekulare Formel:C7H8N2O2
Schmelzpunkt:-
SMILES-Code:O=C(C1=NC=CC(N)=C1)OC
Dichte:
Katalognummer:CM108498
Molekulargewicht:152.15
Siedepunkt:
Mdl-Nr.:MFCD00956000
Lagerung:

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

VX-548
Vertex announced positive results from its Phase 2 dose-ranging study of VX-548 in people with painful diabetic peripheral neuropathy (DPN). VX-548 is an investigational oral, selective NaV1.8 inhibitor that is highly selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that plays a critical role in pain signaling in the peripheral nervous system. NaV1.8 is a genetically validated target for the treatment of pain. Vertex's strategy is to develop new drug types by selectively inhibiting NaV1.8. Compared to opioid drugs, they may provide better analgesic effects while avoiding side effects such as addiction. VX-548 has been granted Breakthrough Therapy and Fast Track designations in the U.S. for moderate to severe acute pain.